Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

mounts due from related parties

-

99 

 Inventories

1,259

2,065 

 Prepayments and other current assets

4,779

4,567 

 Deferred tax assets

315

- 

Total current assets73,10969,382Non-current assets: 

 Derivative assets

261

- 

 Property, plant, equipment and software, net

60,147

70,450 

 Land use right, net

4,221

7,352 

 Other long-term assets

204

791 

Total non-current assets64,83378,593 

Total assets137,942147,975LIABILITIESCurrent liabilities: 

 Short-term bank borrowings

755

773 

 Accounts payable

10,549

11,664 

 Amounts due to related parties

1,025

1,502 

 Salary and welfare payable

4,040

2,774 

 Income tax payable

1,910

931 

 Advance from customers

1,650

1,012 

 Other payables and accruals

4,477

5,055 

 Deferred tax liabilities

-

335 

Total current liabilities24,40624,046 

Total liabilities24,40624,046Commitments and contingenciesEQUITY 

Ordinary shares (US$0.001 par value; 429,999,350 shares authorized;
335,600,000 shares issued and outstanding as of December 31, 2010
and June 30, 2011, respectively)

336

336 

Additional paid in capital

78,989

81,403 

Statutory reserves

6,795

6,795 

Retained earnings

23,655

30,019 

Accumulated other comprehensive income

3,761

5,376 

Total equity113,536123,929 <
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
2. ShangPharma Announces First Quarter 2011 Results
3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
8. Neurologix Announces Second Quarter 2011 Financial Results
9. Bion Announces New U.S. Patent for Phosphorus Removal
10. ViaCyte Announces Executive Management Changes
11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and ... the addition of Jain PharmaBiotech,s new report ... to their offering. , Gene ... vectors, nonviral vectors and cell therapy with genetically ... of drug delivery and various routes of administration ...
(Date:3/3/2015)... PHILADELPHIA , March 3, 2015 ... agencies with tools for implementing competency-based training to comply ... DirectCourse is offering a new crosswalk ... Services (HCBS) implement competency-based training for direct service workers ... Medicare & Medicaid Services (CMS) regulations. CMS ...
(Date:3/3/2015)... 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... focus on protecting the microbiome, announced today that Jeffrey ... the 27th Annual ROTH Conference being held on March 8-11, ... in Dana Point, CA. Mr. Riley ... 1:00 p.m. (Pacific Time). A live webcast of ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Chimerix, Inc., a pharmaceutical company developing orally-available ... Advanced Research and Development Authority (BARDA) of the United ... will resolve the Government Accountability Office (GAO) review of ... Inc. for the development and delivery of a smallpox ...
... is building its reputation as a bioscience center with ... Healthcare of Atlanta, two Metro Atlanta Chamber (MAC) board ... "Atlanta has a thriving bioscience community, and this pediatric ... will benefit patients not just in Georgia, but throughout ...
... With a 150 year expertise in the genetic ... a globally focused outlook, New Zealand,s biotech industry is ... and products. Led by industry organization NZBIO and New ... companies are showcasing their capabilities in human health care, ...
Cached Biology Technology:Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 2Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 3Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 4MAC Members Grow Atlanta's Bioscience Reputation 2MAC Members Grow Atlanta's Bioscience Reputation 3New Zealand Brings Its Global "Game Plan" to the 2011 BIO International Convention 2
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... The malaria parasite has been studied for decades, but ... humans to cause disease. In a groundbreaking study published ... an international research team has for the first time ... or off during actual infection in humans, not in ...
... the past 17 years for extracting oil is now at ... in Canada. Duvernay Petroleum is to use the ... of Bath at its site at Peace River in Alberta, ... viscous, like syrup, or even solid in its natural state ...
... HAYWARD, Calif., Nov. 27 Singulex Inc. today ... Research to develop,immunoassays on the company,s Erenna(TM) system. ... part of its Erenna Technology Access Program,(ETAP) and ... to accurately,and precisely measure specific biomarkers in human ...
Cached Biology News:Study of malaria parasite in patient blood finds distinct physiological states 2Study of malaria parasite in patient blood finds distinct physiological states 3Study of malaria parasite in patient blood finds distinct physiological states 4Massive Canadian oilfield could be exploited using new UK system 2Massive Canadian oilfield could be exploited using new UK system 3Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design 2
... structurally and functionally related BMPs, which are ... originally identified as protein regulators of cartilage ... in embryogenesis and morphogenesis of various tissues ... chemotaxis and apoptosis of various cell types, ...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
RABBIT ANTI HUMAN CHYMOTRYPSIN...
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Biology Products: